Cover Image
市場調查報告書

肝臟疾病治療藥:全球市場

Liver Disease Treatments: The Global Market

出版商 BCC Research 商品編碼 228066
出版日期 內容資訊 英文 141 Pages
訂單完成後即時交付
價格
Back to Top
肝臟疾病治療藥:全球市場 Liver Disease Treatments: The Global Market
出版日期: 2015年06月11日 內容資訊: 英文 141 Pages
簡介

全球肝臟疾病治療藥市場2014年約245億美金,預計到2019年以6.7%的年複合成長率推移,至2019年接近338億美元。

本報告提供全球肝臟疾病治療藥市場現況與展望調查分析、肝臟疾病種類與概要、被治療治療的主要藥物種類與概要、全球主要地區的肝臟疾病的罹患率、各藥物類型、疾病區分、地區的市場規模實際成果預測、法律制度、藥物開發趨勢等的市場影響因素分析、主要製造商、供給業者的市場佔有率、主要企業簡介等彙整,為您概述為以下內容。

第1章 簡介

第2章 摘要整理

第3章 概要

  • 肝臟
  • 定義
  • 肝臟的工作
  • 肝臟疾病的一般症狀
  • 肝臟疾病
  • 中毒性肝損傷
  • 病原體、寄生蟲
  • 免疫障礙
  • 腫瘤
  • 遺傳性肝疾病
  • 其他的疾病、症狀

第4章 治療的分類:各疾病、產品種類

  • 病毒性肝疾病、肝炎
  • 抗病毒藥物
  • 肝腫瘤、肝臟癌症
  • 先天性肝損傷
  • 酒精性肝臟疾病
  • 慢性肝臟疾病
  • 非酒精性脂肪肝病

第5章 法律制度

第6章 罹患率

  • 美國
  • 歐洲
  • 其他地區

第7章 市場:各疾病類型

  • 肝炎
  • 肝細胞癌症
  • 自體免疫性肝損傷
  • 酒精性肝臟疾病
  • 慢性肝臟疾病
  • 非酒精性脂肪肝病

第8章 開發平台

第9章 藥物誘發性肝臟疾病

  • 有引起肝臟疾病可能性的主要藥物

第10章 現狀、未來展望

  • 罹患率、壽命
  • 教育不足、有限的治療選項
  • 研究開發
  • 團體

第11章 專利分析

第12章 企業簡介

  • ABBOTT LABORATORIES
  • ACHILLION PHARMACEUTICALS
  • ACTAVIS INC.
  • ALKERMES
  • ANTIPODEAN PHARMACEUTICALS
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOTEST
  • BRISTOL-MYERS SQUIBB
  • CONATUS PHARMACEUTICALS
  • ELI LILLY
  • GALECTIN THERAPEUTICS
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE
  • GLOBEIMMUNE
  • GRIFOLS INTERNATIONAL
  • INTERCEPT PHARMACEUTICALS
  • ISIS PHARMACEUTICALS
  • Kyowa Hakko Kirin
  • MERCK & CO.
  • NOVARTIS
  • OCERA THERAPEUTICS INC.
  • PEREGRINE
  • PFIZER
  • ROCHE
  • ROXANE LABORATORIES
  • SALIX PHARMACEUTICALS
  • SCHERING PLOUGH CORP.
  • 武田藥品工業
  • VALEANT PHARMACEUTICALS
  • VERTEX PHARMACEUTICALS INC.
  • XIAMEN AMOYTOP BIOTECH
  • ZYDUS PHARMACEUTICALS INC.

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHM057C

REPORT HIGHLIGHTS

The global liver diseases therapeutics market totaled nearly $24.5 billion in 2014 and is projected to approach $33.8 billion by 2019, registering a compound annual growth rate (CAGR) of 6.7% through 2019.

This report provides:

  • An overview of the global market for liver disease treatment and related technologies.
  • Analyses of global market trends, with data from 2013 and 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Information regarding market sizes, market leaders, market dynamics, and various other market factors, as well as the liver disease treatment market for end users.
  • Analysis of different liver disease drugs in response to an increasing need for new and innovative drug treatments.
  • Comprehensive profiles of major players as well as the acquisitions, mergers, and alliances by these companies and global organizations.

SCOPE OF THE STUDY

The scope of this study encompasses liver disease drug markets by various types. BCC Research analyzes each market by category with its applications in different regions of the world. It also analyzes the regulatory environment, technology and market projections. Application issues include the latest trends and developments in each liver disease drug category.

ANALYST'S CREDENTIALS

Yogita Zutshi has 15 years of industry experience working in the areas of clinical research operations, medico/regulatory writing and market research in the pharmaceutical area. She has an MS in Organic Chemistry, an MS in Clinical Research and a Bachelor's in Education. She has also worked on research projects in clinical data management, and has developed training modules for the clinical and pharmacovigilance areas.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASON FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • THE LIVER
  • DEFINITIONS
  • FUNCTIONS OF LIVER
    • PRODUCTION OF BILE
    • STORAGE OF FATS, CARBOHYDRATES, PROTEINS, VITAMINS, AND MINERALS
    • REGULATION OF NECESSARY SUBSTANCES IN THE BLOOD
    • SYNTHESIS OF COAGULATING PROTEINS
    • REMOVAL OF HARMFUL SUBSTANCES
    • OTHER FUNCTIONS
  • COMMON SYMPTOMS OF LIVER DISEASE
    • FATIGUE
    • JAUNDICE
    • SWOLLEN ABDOMEN
    • EFFECTS OF HORMONAL IMBALANCE
    • STOOL ABNORMALITIES
    • POLYDYPSIA AND POLYURIA
    • HEPATIC ENCEPHALOPATHY
    • SEXUAL DYSFUNCTION
    • NON-SPECIFIC SYMPTOMS OF LIVER DISEASE
  • LIVER DISEASE
    • TABLE 1 CLASSIFICATION OF LIVER DISEASE
  • TOXIC INJURY TO THE LIVER
    • Drug-induced Liver Disease
    • Industrial and Environmental Toxins
    • Alcohol-induced
    • Postoperative Hepatic Dysfunction
  • INFECTIOUS AGENTS AND PARASITES
    • Hepatitis Virus
      • Hepatitis A
      • Hepatitis B
      • Hepatitis C
      • Hepatitis D
      • Hepatitis E
      • Neonatal Hepatitis
    • Bacterial and Other Pathogenic Agents
    • Parasites
  • IMMUNE DISORDERS
    • Autoimmune Hepatitis
    • Primary Biliary Cirrhosis
  • TUMORS
    • Primary Malignant Tumors
    • Metastatic Malignant Tumors
    • Benign Hepatic Tumors
    • Tumor-like Lesions
  • INHERITED LIVER DISEASES
    • Wilson's Disease
    • Alagille Syndrome
    • Hemochromatosis
    • Inborn Errors
    • Alpha-1 Antitrypsin Deficiency
    • Cysts
    • Galactosemia
    • Gilbert's Syndrome
    • Tyrosinemia
  • MISCELLANEOUS DISEASES AND CONDITIONS
    • Non-alcoholic Fatty Liver Disease
    • Biliary Atresia
    • Cirrhosis
    • Hepatic Encephalopathy
    • Variceal Bleeding
    • Fatty Liver Disease
    • Gallstones
    • Reye's Syndrome
    • Sarcoidosis

CHAPTER 4 - CLASSIFICATION OF THERAPIES BY DISEASE AND PRODUCTS ON THE MARKET

  • VIRUS-INDUCED LIVER DISEASE AND HEPATITIS
    • VIRAL VACCINES
      • TABLE 2: VACCINES FOR HEPATITIS A PREVENTION
      • TABLE 3: VACCINES FOR HEPATITIS B PREVENTION
  • ANTIVIRAL DRUGS
    • Nucleoside Analogs
      • TABLE 4: NUCLEOSIDE ANALOGS USED TO TREAT HEPATITIS
    • Nucleotide Analogs
      • TABLE 5: NUCLEOTIDE ANALOGS USED TO TREAT HEPATITIS
    • Interferon
      • TABLE 6: INTERFERONS USED TO TREAT HEPATITIS
    • Protease Inhibitors
      • TABLE 7: PROTEASE INHIBITORS USED TO TREAT HEPATITIS
    • Immunoglobulins
      • TABLE 8: IMMUNOGLOBULINS USED TO TREAT HEPATITIS
  • LIVER TUMORS AND LIVER CANCER
    • CHEMOTHERAPEUTIC DRUGS
      • TABLE 9: CHEMOTHERAPEUTIC DRUGS USED TO TREAT LIVER CANCER
    • TARGETED THERAPY
      • TABLE 10: TARGETED THERAPY USED TO TREAT LIVER CANCER
  • CONGENITAL LIVER DEFECTS
    • AUTOIMMUNE LIVER DISEASES
      • TABLE 11: DRUGS USED TO TREAT WILSON'S DISEASE
    • CORTICOSTEROIDS
      • TABLE 12: CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITIS
    • IMMUNOSUPPRESSIVE AGENTS
      • TABLE 13: IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS
    • ANTIMETABOLITES
      • TABLE 14: ANTIMETABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
  • ALCOHOL-INDUCED LIVER DISEASE
    • ANABOLIC STEROIDS
      • TABLE 15: ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DISEASE
    • ALCOHOL-ABUSE DRUGS
      • TABLE 16: ALCOHOL-ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DISEASE
  • CHRONIC LIVER DISEASE
    • ANTI-REJECTION MEDICATIONS
      • TABLE 17: ANTI-REJECTION MEDICATIONS USED TO TREAT CHRONIC LIVER DISEASE
    • ANTI-INFECTIVES
      • TABLE 18: ANTI-INFECTIVES DRUGS USED TO TREAT CHRONIC LIVER DISEASE
    • ANTIFUNGAL PROPHYLAXIS
      • TABLE 19: ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS
  • NON-ALCOHOLIC FATTY LIVER DISEASE
    • GALLSTONE-SOLUBILIZING AGENTS
      • TABLE 20: GALLSTONE-SOLUBILIZING AGENTS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE
    • OTHER DRUGS
      • TABLE 21: OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE

CHAPTER 5 - REGULATORY ASPECTS

  • TABLE 22: NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
  • TABLE 23: NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
  • FIGURE 1: NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
  • TABLE 24: NEW DRUG APPLICATIONS, 2008-2013
  • TABLE 25: RECALLS, 2008-2014

CHAPTER 6 - PREVALENCE

  • U.S.
    • TABLE 26: U.S. PREVALENCE OF LIVER DISEASE, 2000-2020 (NUMBER)
    • TABLE 27: U.S. HEPATITIS BURDEN, 2013 (NO. OF INFECTIONS)
  • EUROPE
  • REST OF THE WORLD

CHAPTER 7 - MARKET BY DISEASE TYPE

  • TABLE 28: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, THROUGH 2019 ($ MILLIONS)
  • FIGURE 2: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, 2012-2019 ($ MILLIONS)
  • HEPATITIS
    • TABLE 29: GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 3: GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, 2012-2019 ($ MILLIONS)
  • HEPATOCELLULAR CARCINOMA
    • TABLE 30: GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 4: GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, 2012-2019 ($ MILLIONS)
  • AUTOIMMUNE LIVER DISEASES
    • TABLE 31: GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 5: GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
  • ALCOHOL-INDUCED LIVER DISEASE
    • TABLE 32: GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 6: GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
  • CHRONIC LIVER DISEASE
    • TABLE 33: GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 7: GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, 2012-2019 ($ MILLIONS)
  • NON-ALCOHOLIC FATTY LIVER DISEASE
    • TABLE 34: GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 8: GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 20120-2019 ($ MILLIONS)

CHAPTER 8 - PIPELINE

  • TABLE 35: CLINICAL TRIALS FOR LIVER DISEASES BY PHASE
  • TABLE 36: NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY PHASE
  • FIGURE 9: NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY PHASE

CHAPTER 9 - DRUG-INDUCED LIVER DISEASE

  • TABLE 37: DRUGS THAT CAN CAUSE LIVER DISEASE
  • MAJOR DRUGS THAT CAN CAUSE LIVER DISEASE
    • ACETAMINOPHEN (TYLENOL)
    • STATINS
    • NICOTINIC ACID (NIACIN)
    • AMIODARONE (CARDARONE)
    • NITROFURANTOIN
    • AUGMENTIN

CHAPTER 10 - CURRENT SITUATION AND FUTURE PROSPECTS

  • PREVALENCE AND LIFE EXPECTANCY
  • LACK OF EDUCATION AND LIMITED TREATMENT OPTIONS
  • RESEARCH AND DEVELOPMENT
  • LIVER ORGANIZATIONS

CHAPTER 11 - PATENT ANALYSIS

  • TABLE 38: NUMBER OF U.S. PATENTS FOR DRUGS USED TO TREAT LIVER DISEASE BY COMPANY, 2012-NOVEMBER, 2014
  • TABLE 39: LIST OF PATENTS ISSUED, 2012-2014
  • TABLE 40: LIST OF PATENT APPLICATIONS, 2012-2014

CHAPTER 12 - COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ACHILLION PHARMACEUTICALS
  • ACTAVIS INC.
  • ALKERMES
  • ANTIPODEAN PHARMACEUTICALS
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOTEST
  • BRISTOL-MYERS SQUIBB
  • CONATUS PHARMACEUTICALS
  • ELI LILLY
  • GALECTIN THERAPEUTICS
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE
  • GLOBEIMMUNE
  • GRIFOLS INTERNATIONAL
  • INTERCEPT PHARMACEUTICALS
  • ISIS PHARMACEUTICALS
  • KYOWA HAKKO KIRIN
  • MERCK & CO.
  • NOVARTIS
  • OCERA THERAPEUTICS INC.
  • PEREGRINE
  • PFIZER
  • ROCHE
  • ROXANE LABORATORIES
  • SALIX PHARMACEUTICALS
  • SCHERING PLOUGH CORP.
  • TAKEDA PHARMACEUTICAL
  • VALEANT PHARMACEUTICALS
  • VERTEX PHARMACEUTICALS INC.
  • XIAMEN AMOYTOP BIOTECH
  • ZYDUS PHARMACEUTICALS INC.

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 1: CLASSIFICATION OF LIVER DISEASE
    • TABLE 2: VACCINES FOR HEPATITIS A PREVENTION
    • TABLE 3: VACCINES FOR HEPATITIS B PREVENTION
    • TABLE 4: NUCLEOSIDE ANALOGS USED TO TREAT HEPATITIS
    • TABLE 5: NUCLEOTIDE ANALOGS USED TO TREAT HEPATITIS
    • TABLE 6: INTERFERONS USED TO TREAT HEPATITIS
    • TABLE 7: PROTEASE INHIBITORS USED TO TREAT HEPATITIS
    • TABLE 8: IMMUNOGLOBULINS USED TO TREAT HEPATITIS
    • TABLE 9: CHEMOTHERAPEUTIC DRUGS USED TO TREAT LIVER CANCER
    • TABLE 10: TARGETED THERAPY USED TO TREAT LIVER CANCER
    • TABLE 11: DRUGS USED TO TREAT WILSON'S DISEASE
    • TABLE 12: CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITIS
    • TABLE 13: IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS
    • TABLE 14: ANTIMETABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
    • TABLE 15: ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DISEASE
    • TABLE 16: ALCOHOL-ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DISEASE
    • TABLE 17: ANTI-REJECTION MEDICATIONS USED TO TREAT CHRONIC LIVER DISEASE
    • TABLE 18: ANTI-INFECTIVES DRUGS USED TO TREAT CHRONIC LIVER DISEASE
    • TABLE 19: ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS
    • TABLE 20: GALLSTONE-SOLUBILIZING AGENTS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE
    • TABLE 21: OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE
    • TABLE 22: NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
    • TABLE 23: NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
    • TABLE 24: NEW DRUG APPLICATIONS, 2008-2013
    • TABLE 25: RECALLS, 2008-2014
    • TABLE 26: U.S. PREVALENCE OF LIVER DISEASE, 2000-2020 (NUMBER)
    • TABLE 27: U.S. HEPATITIS BURDEN, 2013 (NO. OF INFECTIONS)
    • TABLE 28: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, THROUGH 2019 ($ MILLIONS)
    • TABLE 29: GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 30: GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 31: GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 32: GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 33: GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 34: GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 35: CLINICAL TRIALS FOR LIVER DISEASES BY PHASE
    • TABLE 36: NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY PHASE
    • TABLE 37: DRUGS THAT CAN CAUSE LIVER DISEASE
    • TABLE 38: NUMBER OF U.S. PATENTS FOR DRUGS USED TO TREAT LIVER DISEASE BY COMPANY, 2012-NOVEMBER, 2014
    • TABLE 39: LIST OF PATENTS ISSUED, 2012-2014
    • TABLE 40: LIST OF PATENT APPLICATIONS, 2012-2014

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 1: NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
    • FIGURE 2: GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, 2012-2019 ($ MILLIONS)
    • FIGURE 3: GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 4: GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 5: GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 6: GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 7: GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, 2012-2019 ($ MILLIONS)
    • FIGURE 8: GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 20120-2019 ($ MILLIONS)
    • FIGURE 9: NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY PHASE 71
Back to Top